Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy

International Journal of Antimicrobial Agents

Volumn 22, Issue 1, 2003, Pages 54-59

  Calza, Leonardo ^a   Manfredi, Roberto ^a   Farneti, Barbara ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Highly active antiretroviral therapy; HIV infection; Hypercholesterolaemia; Hypertriglyceridaemia; Protease inhibitor

Indexed keywords

ANTIVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RITONAVIR; TRIACYLGLYCEROL;

ACUTE PANCREATITIS; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0038046900     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00100-6     Document Type: Article

References (30)

1. Thiébaut R., Dabis F., Malvy D., Jacqmin-Gadda H., Mercié P., Daucourt Valentin V. Serum triglycerides, HIV infection, and highly active antiretroviral therapy, Aquitaine Cohort, France, 1996 to 1998. J. Acquir. Immune Defic. Syndr. 23:2000;261-265.
2. Moyle G.J., Lloyd M., Reynolds B., Baldwin C., Mandalia S., Gazzard B.G. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 15:2001;1503-1508.
3. Calza L., Manfredi R., Chiodo F. Use of fibrates in the management of hyperlipidaemia in HIV-infected patients receiving HAART. Infection. 30:2002;26-31.
4. Hadigan C., Meigs J.B., Corcoran C., et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32:2001;130-139.
5. Dubé M.P., Sprecher D., Henry W.K., et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. 31:2000;1216-1224.
6. Manfredi R., Chiodo F. Management of dyslipidaemia in patients with HIV disease. Clin. Microbiol. Infect. 6:2000;579-584.
7. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 353:1999;2093-2099.
8. Roberts A.D., Muesing R.A., Parenti D.M., et al. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin. Infect. Dis. 29:1999;441-443.
9. Carr A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance due to HIV protease inhibitors. AIDS. 12:1998;F51-F58.
10. Saint-Marc T., Touraine J.L. Buffalo hump in HIV-1 infection. Lancet. 352:1998;319-320.
11. Savès M., Raffi F., Capeau J., et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin. Infect. Dis. 34:2002;1396-1405.
12. Shaw A.J., McLean K.A., Evans B.A. Disorders of fat distribution in HIV infection. Int. J. STD AIDS. 9:1998;595-599.
13. Dong K.L., Bausserman L.L., Flynn M.M., et al. Changes in body habits and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). J. Acquir. Immune Defic. Syndr. 21:1999;107-113.
14. Sullivan A.K., Nelson M.R. Marked hyperlipidaemia on ritonavir therapy. AIDS. 11:1997;938-939.
15. Danner S.A., Carr A., Leonard J.M., et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New Engl. J. Med. 333:1995;1528-1533.
16. Henry K., Melroe H., Hucbsch J., et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 351:1998;1328.
17. Periard D., Talenti A., Sudre P., et al. Atherogenic dyslipidaemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 100:1999;700-705.
18. Passalaris J.D., Sepkowitz K.A., Glesby M.J. Coronary artery disease and human immunodeficiency virus infection. Clin. Infect. Dis. 31:2000;787-797.
19. Flynn T.E., Bricker L.A. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann. Intern. Med. 131:1999;548.
20. Behrens G., Schmidt H., Meyer D., Stoll M., Schmidt R.E. Vascular complications associated with use of HIV protease inhibitors. Lancet. 351:1998;1958.
21. Gallet B., Pulik M., Genet P., Chedin P., Hiltgen M. Vascular complications associated with use of HIV protease inhibitors. Lancet. 351:1998;1958-1959.
22. Mirete G., Masia M., Gutierrez F., Mora A., Escolano C., Maestre A. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur. J. Clin. Microbiol. Infect. Dis. 17:1998;810-811.
23. Rexrode K.M., Carey V.J., Hennekens C.H., et al. Abdominal obesity and coronary heart disease in women. J. Am. Med. Assoc. 280:1998;1843-1848.
24. Neuvonen P.J., Kantola T., Kivisto K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther. 63:1998;332-341.
25. Muck W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs. 56:1998;15-23.
26. Transon C., Leemann T., Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isoenzyme (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur. J. Clin. Pharmacol. 50:1996;209-215.
27. Baldini F., Di Giambenedetto S., Cingolani A., Murri R., Ammassari A., De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS. 14:2000;1660-1662.
28. Saku K., Gartside P.S., Hynd B.A., et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J. Clin. Invest. 75:1985;1702-1712.
29. Adkins J.C., Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 54:1997;615-633.
30. Henry K., Melroe H., Huebesch J., et al. Atorvastatin and gemfibrozil for protease inhibitor-related lipid abnormalities. Lancet. 352:1998;1031-1032.